Later on during the progress of tumor microevolution, the malignant clone apparently takes advantage of the loss of cell surface syndecan-1, as observed through the connection between decreased cell surface syndecan-1 levels and unfavorable prognosis in head and neck tumors and gastric cancers [19–21]. Here, SDC1 is linked to neoplasm.